NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.

Author:

Sloan Andrew E.1,Gilbert Mark R.2,Zhang Peixin3,Aldape Kenneth D.2,Wu Jing4,Rogers Lisa R.5,Wen Patrick Y.6,Barani Igor J.7,Iwamoto Fabio Massaiti8,Raval Raju R.9,Voloschin Alfredo Daniel10,De Groot John Frederick11,Won Minhee3,Mehta Minesh P.12

Affiliation:

1. University Hospital Case Medical Center, Cleveland, OH;

2. The University of Texas MD Anderson Cancer Center, Houston, TX;

3. NRG Oncology Statistics and Data Management Center, Philadelphia, PA;

4. UNC Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC;

5. University Hospital of Cleveland, Cleveland, OH;

6. Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA;

7. Univ of California San Francisco, San Francisco, CA;

8. Columbia University Medical Center, New York, NY;

9. The Ohio State University Wexner Medical Center, Dublin, OH;

10. Emory University, Atlanta, GA;

11. The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX;

12. University of Maryland Medical Center, Baltimore, MD;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3